Xeris Biopharma Holdings, Inc. XERS | NASDAQ
|2026-11-05
Company Overview:
8.4 Year XERS Performance Metrics:
Build Custom Charts
XERS Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for XERS
Based on past 8.4-year performance, here are XERS growth metrics:
Share price CAGR of -2.28%
Dividend CAGR of +0%
Using XERS CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| XERS (DRIP) | XERS - No DRIP | |
|---|---|---|
| Current Price | $16.66 | $16.66 |
| Start Shares | 600.24 | 600.24 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 600.24 | 600.24 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $13.23 | $16.66 |
| Total Dividends | $0 | $0 |
| Final Value | $7,941 | $10,000 |
NOTE: Above numbers are our estimate based on XERS's Dividend and Price CAGR over past 8.4 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Xeris Biopharma Holdings, Inc. (XERS) had its IPO on 2018-06-21, and is traded on NASDAQ stock exchange.
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
XERS website: https://www.xerispharma.com
DCF Model — XERS
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
